• Revenue increased by 9.9% to $13.5 billion
• Underlying EBITDA grew 5.0% to $614 million
• Completed $360 million distribution center renewal program
• Maintained final dividend at NZ 61.5 cents per share
• Targeting Underlying EBITDA of $635M-$655M for FY27

EBOS Group Limited reported its full-year results for FY26, delivering strong revenue growth of 9.9% to $13.5 billion and Underlying EBITDA growth of 5.0% to $614 million. The result was supported by broad-based growth across Healthcare and Animal Care, together with contributions from recent acquisitions. The Group completed its four-year, $360 million distribution center renewal program, positioning it for continued value creation. The final dividend was maintained at NZ 61.5 cents per share, with a payout ratio of 84.5% of Underlying NPAT. EBOS expects to deliver continued growth in FY27, targeting Underlying EBITDA of between $635 million to $655 million, supported by increased network utilisation, expansion of earnings within Retail Pharmacy Brands, continued therapy and geographic expansion in Medical Technology, and new product and customer growth within Animal Care.

FY27 Underlying EBITDA target: $635M-$655M; Capital expenditure: ~$100M; Depreciation and amortisation: $152M-$162M

EBOS expects to deliver continued growth in FY27, supported by the execution of clear divisional priorities and favourable underlying end-market dynamics. The Group is targeting Underlying EBITDA of between $635 million to $655 million, driven by increased network utilisation and productivity across Symbion & Healthcare Distribution, expansion of earnings within Retail Pharmacy Brands, continued therapy and geographic expansion in Medical Technology, and new product and customer growth within Animal Care.